Anna Kitabjian

Investigators examined the time to first event composing of cardiovascular death, myocardial infarction, or stroke.

Investigators examined the frequency of cardiovascular vs noncardiovascular deaths in individuals who developed prediabetes that did not progress to diabetes.

Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.

There were no observable differences in the incidence of any cardiovascular events across the smoking cessation treatment groups.

Further studies are needed to assess whether beta-blockers are effective in reducing mortality and coronary events in patients with diabetes receiving optimal medical treatment.

Compared with standard care, noninvasive coronary artery disease screening reduced cardiac events by 27% in individuals with asymptomatic diabetes. Results justify larger, appropriately powered trials to potentially revisit current recommendations.

Patients with pulmonary arterial hypertension may be better identified with the use of a claims-based algorithm that includes ICD-9-CM codes, electronic medical records, and more.

A 3-month risk for a thromboembolic event was assessed using a pulmonary embolism rule-out criteria strategy and compared with a conventional strategy in patients with a low clinical probability of pulmonary embolism.

Certain risk scores may not be reliable for predicting the presence of a pulmonary embolism in pregnant or postpartum women.

Several drugs may demonstrate different safety profiles and side effects that warrant a change in treatment for individuals with pulmonary hypertension.